Principal Securities Inc. Grows Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Principal Securities Inc. grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 43.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 898 shares of the biopharmaceutical company’s stock after purchasing an additional 274 shares during the period. Principal Securities Inc.’s holdings in Regeneron Pharmaceuticals were worth $640,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Sequoia Financial Advisors LLC lifted its stake in Regeneron Pharmaceuticals by 14.3% in the third quarter. Sequoia Financial Advisors LLC now owns 1,740 shares of the biopharmaceutical company’s stock worth $1,829,000 after purchasing an additional 218 shares during the last quarter. Private Advisor Group LLC lifted its stake in Regeneron Pharmaceuticals by 6.0% in the third quarter. Private Advisor Group LLC now owns 5,361 shares of the biopharmaceutical company’s stock worth $5,635,000 after purchasing an additional 303 shares during the last quarter. Lecap Asset Management Ltd. bought a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at about $1,031,000. Commerzbank Aktiengesellschaft FI raised its stake in shares of Regeneron Pharmaceuticals by 74.0% during the third quarter. Commerzbank Aktiengesellschaft FI now owns 402 shares of the biopharmaceutical company’s stock valued at $423,000 after acquiring an additional 171 shares during the last quarter. Finally, Axecap Investments LLC bought a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at about $2,096,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Sanford C. Bernstein lowered their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research note on Tuesday, January 7th. Wells Fargo & Company decreased their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research note on Friday, January 10th. Leerink Partners raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $762.00 to $834.00 in a research note on Wednesday, February 5th. UBS Group downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Finally, Morgan Stanley decreased their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $696.02 on Friday. The company’s 50-day moving average price is $700.02 and its 200-day moving average price is $886.33. Regeneron Pharmaceuticals, Inc. has a twelve month low of $642.00 and a twelve month high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The company has a market cap of $76.09 billion, a PE ratio of 18.18, a price-to-earnings-growth ratio of 2.28 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm’s revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $11.86 EPS. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be issued a dividend of $0.88 per share. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.51%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.